Diflucan can be considered for treatment of Malassezia folliculitis.

Prophylaxis in neutropenic patients is a common use, guided by local resistance patterns.

Resistance to Diflucan is a growing concern, particularly with Candida glabrata and krusei.

Not effective against Histoplasma in the central nervous system due to poor penetration (unlike itraconazole).

Diflucan is intrinsically ineffective against Mucorales, necessitating alternative therapy.

A valuable agent in antimicrobial stewardship programs due to its specificity.

Efficacy in peritoneal candidiasis is supported by good peritoneal penetration.

Diflucan may have in vitro synergy with flucytosine against some Candida species.

Diflucan can be a cost-effective alternative to more expensive antifungals when susceptibility is confirmed.

Diflucan can increase sulfonylurea levels, increasing hypoglycemia risk.